RADNOR, Pa.–(Business Wire)–
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on
developing new therapeutic drugs to treat acute cardiovascular disorders and
infectious diseases, will be presenting at the Noble Financial Sixth Annual
Equity Conference. The Conference will take place June 7-8, 2010 at the Hard
Rock Hotel in Hollywood, Florida.

Edward Smith, Vice President of Finance & CFO of PolyMedix will present on
Tuesday, June 8, 2010 at 1:30 PM ET. The presentation will be webcast live and
may be accessed on the Company`s website at www.polymedix.com. A replay will be
available for 90 days following the event.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development
of novel drugs and biomaterials for the treatment of serious acute
cardiovascular disorders and infectious diseases. PolyMedix uses a rational drug
design approach to create non-peptide small molecule drug candidates and
polymers that mimic the activity of proteins. PMX-60056, PolyMedix`s lead
heptagonist compound, is being developed to reverse the anticoagulant activity
of both heparin and low molecular weight heparins. PolyMedix believes that
PMX-60056 could potentially be a safer and easier to use anticoagulant reversing
agent, with broader activity, than the currently approved therapy. PMX-30063,
PolyMedix`s lead antibiotic compound, is a small molecule that mimics human
host-defense proteins and has a completely different mechanism of action
distinct from those of current antibiotic drugs, a mechanism which is intended
to make bacterial resistance unlikely to develop. PolyMedix plans to develop
this compound for serious systemic Staphylococcal infections, including MRSA.
Both PMX-60056 heptagonist and PMX-30063 antibiotic are currently undergoing
clinical testing. PolyMedix also plans to continue the development of its
PolyCides, polymeric formulations as antimicrobial biomaterials, which can be
used as additives to paints, plastics, and textiles to create self-sterilizing
products and surfaces. For more information, please visit our website at
www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and assumptions that could cause PolyMedix`s actual
results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. PolyMedix has in
some cases identified forward-looking statements by using words such as
“anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,”
“intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among
other factors that could cause actual results to differ materially from those
expressed in forward-looking statements, PolyMedix`s compounds may not enter or
successfully complete clinical testing, or be granted regulatory approval to be
sold and marketed in the United States or elsewhere. A more complete description
of these risk factors is included in PolyMedix`s filings with the Securities and
Exchange Commission. You should not place undue reliance on any forward-looking
statements. PolyMedix undertakes no obligation to release publicly the results
of any revisions to any such forward-looking statements that may be made to
reflect events or circumstances after the date of this press release or to
reflect the occurrence of unanticipated events, except as required by applicable
law or regulation.

PolyMedix, Inc.
Company:
Lisa Caperelli, 484-598-2406
Director, Investor Relations & Corporate Communications
lcaperelli@polymedix.com
or
Investors:
Erika Moran
emoran@investorrelationsgroup.com
or
Media:
Janet Vasquez, 212-825-3210
jvasquez@investorrelationsgroup.com